Table 4.
Abliglutide (Tanzeum®) clinical trials: changes in weight and hemoglobin A1C [81].
| Study | N | Background OAD | Comparator | A1C reduction with abliglutide | Change in body weight (kg) over study period |
|---|---|---|---|---|---|
| HARMONY I [60] | 1041 | TZD | Placebo | Albiglutide 30 mg: −0.81% | +0.3 |
| HARMONY 2 [32] | 1091 | None | Placebo | Albiglutide 30 mg: −0.84% lbiglutide 50 mg: −1.04% |
−0.4 |
| HARMONY 3 [57] | 746 | MET | Placebo, SU, Sitagliptin | Albiglutide 30–50 mg: −0.63% | −1.21 |
| HARMONY 4 [33] | 533 | MET±SU | Insulin glargine | Albiglutide 30–50 mg: −0.67% | −1.1 |
| HARMONY 5 [59] | 581 | MET±SU | Placebo, pioglitazone | Albiglutide 30–50 mg: −0.55% | −0.4 |
| HARMONY 6 [61] | 464 | Insulin glargine | Insulin glargine+insulin lispro | Albiglutide 30–50 mg: −0.82% | −0.73 |
| HARMONY 7 [34] | Met or SU or TZD | Liraglutide | Albiglutide 50 mg: −0.78% | −0.64 |
OAD, oral antidiabetic drug; TZD, thiazolinedione; MET, metformin; SU, sulfonylurea.